000756 新华制药
已收盘 12-31 15:00:00
资讯
新帖
简况
流感疫情持续，防控系统工程再受考验
证券之星 · 12-31 17:18
流感疫情持续，防控系统工程再受考验
新华制药缬沙坦胶囊获药品注册证书，丰富心血管产品线
中金财经 · 12-30 23:18
新华制药缬沙坦胶囊获药品注册证书，丰富心血管产品线
新华制药间苯三酚注射液获药品注册证书，有望开拓新市场
中金财经 · 12-30 23:18
新华制药间苯三酚注射液获药品注册证书，有望开拓新市场
发力止痛市场，新华制药间苯三酚注射液获批注册
财中社 · 2025-12-29
发力止痛市场，新华制药间苯三酚注射液获批注册
新华制药：获得缬沙坦胶囊、间苯三酚注射液药品注册证书
人民财讯 · 2025-12-29
新华制药：获得缬沙坦胶囊、间苯三酚注射液药品注册证书
新华制药(000756.SZ)获得磷酸奥司他韦干混悬剂药品注册证书
智通财经 · 2025-12-23
新华制药(000756.SZ)获得磷酸奥司他韦干混悬剂药品注册证书
新华制药 - 奥司他韦磷酸酯悬剂获得Nmpa药品注册证书
美股速递 · 2025-12-23
新华制药 - 奥司他韦磷酸酯悬剂获得Nmpa药品注册证书
比饮料还便宜的注射液走到尽头？新华制药冲击创新却遇盈利“滑坡”，58％净利降幅撕开低价模式伤疤
华夏时报网 · 2025-12-22
比饮料还便宜的注射液走到尽头？新华制药冲击创新却遇盈利“滑坡”，58％净利降幅撕开低价模式伤疤
新华制药：公司1年以内应收账款占比超过96%
证券之星 · 2025-12-19
新华制药：公司1年以内应收账款占比超过96%
新华制药：淄博新华大药店连锁有限公司是旗下药店
证券之星 · 2025-12-18
新华制药：淄博新华大药店连锁有限公司是旗下药店
新华制药：布洛芬阿司匹林用于流感治疗
证券之星 · 2025-12-09
新华制药：布洛芬阿司匹林用于流感治疗
新华制药：醋酸泼尼松龙原料药获批，市场竞争添 “新翼”
财中社 · 2025-11-27
新华制药：醋酸泼尼松龙原料药获批，市场竞争添 “新翼”
新华制药：公司并不生产奥司他韦原料药
证券之星 · 2025-11-27
新华制药：公司并不生产奥司他韦原料药
新华制药(000756.SZ)：盐酸肾上腺素注射液通过一致性评价
智通财经 · 2025-11-27
新华制药(000756.SZ)：盐酸肾上腺素注射液通过一致性评价
新华制药- 丙戊酸氟氯噻吨的营销申请获得中国NMPA批准
美股速递 · 2025-11-27
新华制药- 丙戊酸氟氯噻吨的营销申请获得中国NMPA批准
新华制药(000756.SZ)：利丙双卡因乳膏取得药品注册证书
智通财经 · 2025-11-25
新华制药(000756.SZ)：利丙双卡因乳膏取得药品注册证书
新华制药 - 利多卡因和普鲁卡因软膏获得中国NMPA药品注册证书
美股速递 · 2025-11-25
新华制药 - 利多卡因和普鲁卡因软膏获得中国NMPA药品注册证书
异动快报：新华制药（000756）11月25日13点6分触及涨停板
证券之星 · 2025-11-25
异动快报：新华制药（000756）11月25日13点6分触及涨停板
新华制药(000756.SZ)：富马酸伏诺拉生化学原料药上市申请获批准
智通财经 · 2025-11-17
新华制药(000756.SZ)：富马酸伏诺拉生化学原料药上市申请获批准
新华制药：全球重要解热镇痛类药物生产商
证券之星 · 2025-11-05
新华制药：全球重要解热镇痛类药物生产商
加载更多
公司概况
公司名称：
山东新华制药股份有限公司
所属行业：
医药制造业
上市日期：
1997-08-06
主营业务：
山东新华制药股份有限公司的主营业务是开发、制造和销售化学原料药、制剂及化工产品。公司的主要产品是“新华牌”解热镇痛类药物、心脑血管类、抗感染类及中枢神经类等药物。1个项目获山东省2024年度科技进步二等奖。
发行价格：
3.45
{"stockData":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":15.41,"timestamp":1767164634000,"preClose":15.53,"halted":0,"volume":8911427,"delay":0,"changeRate":-0.0077,"floatShares":493000000,"shares":690000000,"eps":0.5541,"marketStatus":"已收盘","change":-0.12,"latestTime":"12-31 15:00:00","open":15.55,"high":15.58,"low":15.4,"amount":138000000,"amplitude":0.0116,"askPrice":15.42,"askSize":647,"bidPrice":15.41,"bidSize":1299,"shortable":0,"etf":0,"ttmEps":0.5541,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":15.53,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":17.08,"lowLimit":13.98,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":689776535,"isCdr":false,"pbRate":2.08,"roa":"--","peRate":27.810864,"roe":"5.01%","epsLYR":0.69,"committee":0.445688,"marketValue":10629000000,"turnoverRate":0.0181,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-01-05。","hkstockBrief":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":6.64,"timestamp":1767326700002,"preClose":6.59,"halted":0,"volume":64000,"delay":0,"premium":"-61.42"},"floatMarketCap":7591000000},"requestUrl":"/m/hq/s/000756","defaultTab":"news","newsList":[{"id":"2595127727","title":"流感疫情持续，防控系统工程再受考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2595127727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595127727?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172695,"startTime":"0","endTime":"0","summary":"2025年末，全国流感疫情持续处于高流行水平。产业链协同响应，构建多层次供应保障流感防控是一项系统工程，需要疫苗预防、快速诊断、药物治疗等多个环节的有效衔接。本轮疫情中，上市药企正通过全产业链布局，搭建从源头预防到终端治疗的健康保障网络。中成药在本轮疫情中表现活跃。公司表示，金振口服液四季度市场需求回暖，正加紧排产满足市场需要。随着该产品儿童流感新适应症的获批，其在儿科领域的应用场景进一步拓宽。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025123100030908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300937","BK0146","BK0188","BK0060","BK0201","002603","BK0175","000756","600566","300244","BK0183","BK0046","BK0028","BK0239","000999","BK0185","BK0186","BK0114","000623","BK0042","BK0070","BK0086","BK0164","BK0196","600557","600079","603858","BK0012","BK0096","002393","SG9999001069.SGD","BK0197","BK0010","BK0077","BK0187","301207","603882","002317","BK0097","BK0236","688276","BK0284","BK0074","002728","BK0250"],"gpt_icon":0},{"id":"2595715567","title":"新华制药缬沙坦胶囊获药品注册证书，丰富心血管产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2595715567","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595715567?lang=zh_cn&edition=full","pubTime":"2025-12-30 23:18","pubTimestamp":1767107900,"startTime":"0","endTime":"0","summary":"中访网数据 山东新华制药股份有限公司于近日宣布，其申报的缬沙坦胶囊已获得国家药品监督管理局核发的《药品注册证书》。该药品注册分类为化学药品4类，获批用于治疗轻、中度原发性高血压。缬沙坦胶囊属于《国家基本医疗保险、工伤保险和生育保险药品目录》甲类品种。此次获批标志着新华制药在心脑血管疾病治疗领域的产品管线得到进一步丰富，有望提升公司在该领域的市场竞争力与综合实力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31905046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2595155977","title":"新华制药间苯三酚注射液获药品注册证书，有望开拓新市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2595155977","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595155977?lang=zh_cn&edition=full","pubTime":"2025-12-30 23:18","pubTimestamp":1767107900,"startTime":"0","endTime":"0","summary":"中访网数据 山东新华制药股份有限公司近日宣布，其申报的间苯三酚注射液已获得国家药品监督管理局核准签发的《药品注册证书》。本品主要用于治疗消化系统、胆道功能障碍以及泌尿系统、妇科相关的急性痉挛性疼痛。新华制药表示，此次获得药品注册证书，将有利于公司开拓新的市场领域，提升市场竞争力。同时，公司也提示投资者，药品销售可能受到行业政策、招标采购及市场环境变化等因素影响，存在不确定性风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31905047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2595994786","title":"发力止痛市场，新华制药间苯三酚注射液获批注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2595994786","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595994786?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:41","pubTimestamp":1767001274,"startTime":"0","endTime":"0","summary":"12月29日，新华制药（000756/00719）发布公告，公司的药品“间苯三酚注射液”符合药品注册的有关要求，获批注册。间苯三酚注射液用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉挛性疼痛。根据相关统计数据，2024年中国公立医疗机构间苯三酚注射液销售额约为9亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604513393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2595785549","title":"新华制药：获得缬沙坦胶囊、间苯三酚注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2595785549","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595785549?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:08","pubTimestamp":1766999328,"startTime":"0","endTime":"0","summary":"人民财讯12月29日电，新华制药(000756)12月29日公告，公司近日收到国家药监局核准签发的缬沙坦胶囊、间苯三酚注射液《药品注册证书》。缬沙坦胶囊用于治疗轻、中度原发性高血压。间苯三酚注射液用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉挛性疼痛。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604479435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2593271493","title":"新华制药(000756.SZ)获得磷酸奥司他韦干混悬剂药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593271493","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593271493?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:08","pubTimestamp":1766480934,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的磷酸奥司他韦干混悬剂(以下简称“本品”)《药品注册证书》。本品用于2周龄及以上年龄患者的甲型和乙型流感治疗(磷酸奥司他韦能够有效治疗甲型和乙型流感，但是乙型流感的临床应用数据尚不多)。患者应在首次出现症状48小时以内使用。本品也可用于1岁及1岁以上人群的甲型和乙型流感的预防。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)获得磷酸奥司他韦干混悬剂药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"1153706211","title":"新华制药 - 奥司他韦磷酸酯悬剂获得Nmpa药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1153706211","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153706211?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:52","pubTimestamp":1766479964,"startTime":"0","endTime":"0","summary":"新华制药 - 奥司他韦磷酸酯悬剂获得Nmpa药品注册证书","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2593148464","title":"比饮料还便宜的注射液走到尽头？新华制药冲击创新却遇盈利“滑坡”，58％净利降幅撕开低价模式伤疤","url":"https://stock-news.laohu8.com/highlight/detail?id=2593148464","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593148464?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:22","pubTimestamp":1766402551,"startTime":"0","endTime":"0","summary":"比饮料还便宜的注射液走到尽头？新华制药冲击创新却遇盈利“滑坡”，58％净利降幅撕开低价模式伤疤","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512223598439969.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598439969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2592152683","title":"新华制药：公司1年以内应收账款占比超过96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592152683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592152683?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:48","pubTimestamp":1766134086,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药(000756)12月19日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘，公司应收账款等于3年利润，如果出现坏账是否有应对？谢谢新华制药回复：您好！正如公司2025年半年报所描述，公司1年以内应收账款占比超过96%，应收账款结构相对健康。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900024026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2592975545","title":"新华制药：淄博新华大药店连锁有限公司是旗下药店","url":"https://stock-news.laohu8.com/highlight/detail?id=2592975545","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592975545?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:15","pubTimestamp":1766045731,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药(000756)12月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，新华大药房是不是属于新华制药旗下药店，在山东当地有多少连锁店。。经营效益如何？新华制药回复：您好！淄博新华大药店连锁有限公司是新华制药旗下药店，其连锁店主要在山东省内。有关经营情况，请见公司于巨潮资讯网刊载的定期报告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800020592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2590917315","title":"新华制药：布洛芬阿司匹林用于流感治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2590917315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590917315?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:00","pubTimestamp":1765267232,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药(000756)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：疫情最近严重，公司有哪些流感药新华制药回复：您好！新华制药是全球重要的解热镇痛类药物生产商，公司生产的布洛芬、阿司匹林等药物广泛应用于流感相关症状的治疗。新华制药有帕拉米韦注射液，这是一种新一代神经氨酸酶抑制剂，可用于治疗全年龄段的甲型或乙型流行性感冒患者。公司产品名录参见公司官网https://www.xhzy.com/。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900019642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2586458322","title":"新华制药：醋酸泼尼松龙原料药获批，市场竞争添 “新翼”","url":"https://stock-news.laohu8.com/highlight/detail?id=2586458322","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586458322?lang=zh_cn&edition=full","pubTime":"2025-11-27 17:05","pubTimestamp":1764234312,"startTime":"0","endTime":"0","summary":"11月27日，新华制药（000756/00719）发布公告，近日公司收到国家药品监督管理局核准签发的醋酸泼尼松龙《化学原料药上市申请批准通知书》。该原料药主要用于治疗过敏性与自身免疫性炎症疾病，包括活动性风湿、类风湿性关节炎等，符合药品注册的有关要求，批准注册后将进一步丰富公司的激素类产品线，提升核心竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511273576666693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2586243995","title":"新华制药：公司并不生产奥司他韦原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2586243995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586243995?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:57","pubTimestamp":1764233831,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药(000756)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！从网上资料查到贵司现在已经建成全球最大的奥司他韦原料药生产基地。问情况属实吗？另外在当下甲流高发期希望贵司能做出更大社会贡献！顺祝您工作顺利！新华制药回复：您好！新华制药是全球重要的解热镇痛类药物生产商，公司生产的布洛芬、阿司匹林等药物广泛应用于流感相关症状的治疗。公司并不生产奥司他韦原料药，公司产品名录请参见公司官网https://www.xhzy.com/。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700024215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2586248079","title":"新华制药(000756.SZ)：盐酸肾上腺素注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2586248079","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586248079?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:46","pubTimestamp":1764233199,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的盐酸肾上腺素注射液《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致性评价。本品主要适用于因支气管痉挛所致严重呼吸困难，可迅速缓解药物等引起的过敏性休克，亦可用于延长浸润麻醉用药的作用时间，是各种原因引起的心脏骤停进行心肺复苏的主要抢救用药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"1107675950","title":"新华制药- 丙戊酸氟氯噻吨的营销申请获得中国NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1107675950","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107675950?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:35","pubTimestamp":1764232509,"startTime":"0","endTime":"0","summary":"新华制药- 丙戊酸氟氯噻吨的营销申请获得中国NMPA批准","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2586423213","title":"新华制药(000756.SZ)：利丙双卡因乳膏取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586423213","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586423213?lang=zh_cn&edition=full","pubTime":"2025-11-25 17:02","pubTimestamp":1764061361,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的利丙双卡因乳膏《药品注册证书》。利丙双卡因乳膏是利多卡因和丙胺卡因的复方制剂，用于下列情况的皮肤局部麻醉：针穿刺，例如：置入导管或采血;浅层外科手术，例如：生殖器粘膜，在浅层外科手术或浸润麻醉之前;腿部溃疡清洁/清创术。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)：利丙双卡因乳膏取得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"1108747914","title":"新华制药 - 利多卡因和普鲁卡因软膏获得中国NMPA药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1108747914","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108747914?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:38","pubTimestamp":1764059911,"startTime":"0","endTime":"0","summary":"新华制药 - 利多卡因和普鲁卡因软膏获得中国NMPA药品注册证书","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2586446297","title":"异动快报：新华制药（000756）11月25日13点6分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2586446297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586446297?lang=zh_cn&edition=full","pubTime":"2025-11-25 13:10","pubTimestamp":1764047447,"startTime":"0","endTime":"0","summary":"证券之星11月25日盘中消息，13点6分新华制药触及涨停板。目前价格16.77，上涨7.5%。其所属行业化学制药目前上涨。领涨股为一品红。该股为化学原料药，阿尔茨海默病，医药概念热股，当日化学原料药概念上涨2.42%，阿尔茨海默病概念上涨2.26%，医药概念上涨2.25%。11月24日的资金流向数据方面，主力资金净流入609.34万元，占总成交额2.29%，游资资金净流入561.47万元，占总成交额2.11%，散户资金净流出1170.81万元，占总成交额4.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500016570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2584645529","title":"新华制药(000756.SZ)：富马酸伏诺拉生化学原料药上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584645529","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584645529?lang=zh_cn&edition=full","pubTime":"2025-11-17 17:01","pubTimestamp":1763370119,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的富马酸伏诺拉生《化学原料药上市申请批准通知书》。该药物主要用于反流性食管炎。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新华制药(000756.SZ)：富马酸伏诺拉生化学原料药上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2581154617","title":"新华制药：全球重要解热镇痛类药物生产商","url":"https://stock-news.laohu8.com/highlight/detail?id=2581154617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581154617?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:33","pubTimestamp":1762313591,"startTime":"0","endTime":"0","summary":"证券之星消息，新华制药(000756)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司解热镇痛类药物属于全国头部企业，且生产的奥司他韦也在市场有一定占有率，请问贵公司概念题材里面为什么没有流感板块的介绍呢？新华制药回复：您好！新华制药是全球重要的解热镇痛类药物生产商，公司生产的布洛芬、阿司匹林等药物广泛应用于流感相关症状的治疗。此外，新华制药有帕拉米韦注射液，这是一种新一代神经氨酸酶抑制剂，可用于治疗全年龄段的甲型或乙型流行性感冒患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500013825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767328816133,"stockEarnings":[{"period":"1week","weight":-0.0247},{"period":"1month","weight":-0.1264},{"period":"3month","weight":-0.0071},{"period":"6month","weight":-0.0337},{"period":"1year","weight":-0.0048},{"period":"ytd","weight":-0.0048}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东新华制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1997-08-06","address":"山东省淄博市张店区高新技术产业开发区化工区","registeredCapital":"68977万元","survey":" 山东新华制药股份有限公司的主营业务是开发、制造和销售化学原料药、制剂及化工产品。公司的主要产品是“新华牌”解热镇痛类药物、心脑血管类、抗感染类及中枢神经类等药物。1个项目获山东省2024年度科技进步二等奖。","listedPrice":3.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新华制药,000756,新华制药股票,新华制药股票老虎,新华制药股票老虎国际,新华制药行情,新华制药股票行情,新华制药股价,新华制药股市,新华制药股票价格,新华制药股票交易,新华制药股票购买,新华制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}